• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by Pfizer Inc.

    < Previous 1 2 3 4 5 6 7 8 9 10 Next >
    Pfizer Announces Submission of New Drug Application to the U.S. FDA for PAXLOVID™
    From Pfizer Inc.
    Via Business Wire
    Tickers PFE
    Pfizer and BioNTech Announce New Agreement with U.S. Government to Provide Additional Doses of COVID-19 Vaccine
    From Pfizer Inc.
    Via Business Wire
    Tickers BNTX PFE
    Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus
    From Pfizer Inc.
    Via Business Wire
    Tickers PFE ROIV
    Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron
    From Pfizer Inc.
    Via Business Wire
    Tickers BNTX PFE
    Pfizer Invites Public to View and Listen to Webcast of July 28 Conference Call with Analysts
    From Pfizer Inc.
    Via Business Wire
    Tickers PFE
    Pfizer Declares Third-Quarter 2022 Dividend
    From Pfizer Inc.
    Via Business Wire
    Tickers PFE
    Valneva and Pfizer Enter into an Equity Subscription Agreement and Update Terms of Collaboration Agreement for Lyme Disease Vaccine Candidate VLA15
    From Pfizer Inc.
    Via Business Wire
    Tickers PFE VALN
    Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Authorization for Children 6 Months through 4 Years of Age
    From Pfizer Inc.
    Via Business Wire
    Tickers BNTX PFE
    Pfizer Reports Additional Data on PAXLOVID™ Supporting Upcoming New Drug Application Submission to U.S. FDA
    From Pfizer Inc.
    Via Business Wire
    Tickers PFE
    Pfizer Completes Acquisition of ReViral
    From Pfizer Inc.
    Via Business Wire
    Tickers PFE
    Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
    From Pfizer Inc.
    Via Business Wire
    Tickers PFE
    Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
    From Pfizer Inc.
    Via Business Wire
    Tickers PFE
    Pfizer to Invest $120 Million to Produce COVID-19 Oral Treatment in the U.S.
    From Pfizer Inc.
    Via Business Wire
    Tickers PFE
    Pfizer Announces Overall Survival Results from Phase 3 PALOMA-2 Trial of IBRANCE® (palbociclib) for the First-Line Treatment of ER+, HER2- Metastatic Breast Cancer
    From Pfizer Inc.
    Via Business Wire
    Tickers PFE
    Pfizer Provides Update on Ownership Interest in Haleon
    From Pfizer Inc.
    Via Business Wire
    Tickers PFE
    Pfizer Invites Public to View and Listen to a Webcast of Pfizer Discussion on Expanding Access & Affordability
    From Pfizer Inc.
    Via Business Wire
    Tickers PFE
    Pfizer Granted FDA Fast Track Designation for Ervogastat/Clesacostat Combination for the Treatment of Non-Alcoholic Steatohepatitis (NASH)
    From Pfizer Inc.
    Via Business Wire
    Tickers PFE
    Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
    From Pfizer Inc.
    Via Business Wire
    Tickers PFE
    Pfizer Launches ‘An Accord for a Healthier World’ to Improve Health Equity for 1.2 Billion People Living in 45 Lower-Income Countries
    From Pfizer Inc.
    Via Business Wire
    Tickers PFE
    Pfizer Presents ELEVATE Pivotal Findings Demonstrating Etrasimod’s Potentially Best-in-Class Profile in Ulcerative Colitis
    From Pfizer Inc.
    Via Business Wire
    Tickers PFE
    Pfizer-BioNTech COVID-19 Vaccine Demonstrates Strong Immune Response, High Efficacy and Favorable Safety in Children 6 Months to Under 5 Years of Age Following Third Dose
    From Pfizer Inc.
    Via Business Wire
    Tickers BNTX PFE
    Pfizer and BioNTech Granted U.S. Emergency Use Authorization for Booster Dose of Their COVID-19 Vaccine in Children 5 Through 11 Years of Age
    From Pfizer Inc.
    Via Business Wire
    Tickers BNTX PFE
    Pfizer to Acquire Biohaven Pharmaceuticals
    From Pfizer Inc.
    Via Business Wire
    Tickers BHVN PFE
    Pfizer Reports First-Quarter 2022 Results
    From Pfizer Inc.
    Via Business Wire
    Tickers PFE
    Pfizer Declares Second-Quarter 2022 Dividend
    From Pfizer Inc.
    Via Business Wire
    Tickers PFE
    Pfizer and Biohaven’s VYDURA® (Rimegepant) Granted First Ever Marketing Authorization by European Commission for Both Acute Treatment of Migraine and Prophylaxis of Episodic Migraine
    From Pfizer Inc.
    Via Business Wire
    Tickers BHVN PFE
    Valneva and Pfizer Report Positive Phase 2 Pediatric Data for Lyme Disease Vaccine Candidate
    From Pfizer Inc.
    Via Business Wire
    Tickers PFE VALN
    Pfizer Invites Shareholders to Attend Virtual-Only 2022 Annual Meeting of Shareholders on April 28
    From Pfizer Inc.
    Via Business Wire
    Tickers PFE
    Pfizer and BioNTech Announce Data Demonstrating High Immune Response Following a Booster Dose of their COVID-19 Vaccine in Children 5 Through 11 Years of Age
    From Pfizer Inc.
    Via Business Wire
    Tickers BNTX PFE
    Pfizer Names David M. Denton Chief Financial Officer
    From Pfizer Inc.
    Via Business Wire
    Tickers PFE
    < Previous 1 2 3 4 5 6 7 8 9 10 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.